Metropolis Healthcare shares gained 3% on 9 October after the company reported a robust Q2 report with early double-digit growth for its core business.

The company, in its exchange filing, said that its core business revenue( including Hi-tech but excluding Covid, Covid Allied & PPP Contracts) grew by 13% YoY. This revenue growth was largely driven by volume growth and demonstrated strong customer acquisition.

On a sequential basis, the operating margins also grew on account of higher revenues, leading to operating leverage and product mix.

The company’s B2C revenue saw a 15% YoY growth on the back of volume and new patient growth,

Its premium wellness segment is the fastest-growing segment of the company for the quarter under review.

As of 30 September, the company’s gross debt stands at Rs 44 crore.

The Mumbai-based healthcare firm provides a range of super-speciality tests and diagnostics services to its customers through over 150 labs and 2,800 collection centres that are located in 20 states and 61 cities.

The healthcare firm aims to add 90 new labs and 1,800 new collection centres by FY 2025.

At 12:42 pm, the shares of Metropolis Healthcare were trading at Rs 1,500.95 or 2.03% above its previous close on NSE.